HORIBA announces new Veloci BioPharma Analyzer for biopharma and pharma applications

HORIBA has launched Veloci^™, a biopharma analyzer with A-TEEM^™ Technology (simultaneous Absorbance, Transmittance, and Fluorescence Excitation-Emission-Matrix (EEM)), providing advanced molecular fingerprinting for life science applications.

The BioPharma Analyzer is a unique A-TEEM^™ spectroscopy solution for the biopharma and pharma industries that combines the selectivity of chromatography with the advantages of optical spectroscopy. This technology provides a fast, cost-effective, and user-friendly approach to component analysis and eliminates the need for traditional column-based separations.

The Veloci BioPharma Analyzer utilizes label-free intrinsic fluorescence analysis, providing unprecedented precision and efficiency over a wide range of applications, including monoclonal antibody discrimination, cell media monitoring, vaccine characterization, protein stability analysis, and adeno-associated virus (AAV) quantification.

The Analyzer combines the selectivity of chromatography with the speed and simplicity of spectroscopy providing superior sensitivity versus traditional methods such as high performance liquid chromatography (HPLC)/mass spectrometry (MS) and Raman spectroscopy. It requires no sample preparation or solvent use, and it accelerates workflows, with analysis times as short as three minutes per sample for the hundreds of EEM spectra acquired and processed, compared to 30 minutes for traditional methods like ultra performance liquid chromatography (UPLC), hereby reducing both time and environmental impact.

The Veloci ™A-TEEM™ BioPharma Analyzer can:

• when analyzing antibody drug conjugates, distinguish between the monoclonal antibodies (mAbs) portion of the drug, the payload, and the linker with over 90% sequence homology, delivering rapid and accurate intrinsic fluorescence analysis in their natural state.

• Measure capsid empty/full ratios and differentiate AAV subtypes in a label-free manner, bypassing the need for analytical centrifuges.

• Monitor cell culture media quality for bioreactors.

• Provide vaccine characterization by identifying formulations, detecting aggregation, and monitoring batch-to-batch variations.

• Offer protein stability by detecting early signs of aggregation, safeguarding against reduced potency and increased side effects.

• Discriminate between exosome subtypes, enabling advanced studies on extracellular signaling and therapeutic applications.

Cary Davies, global product line manager for fluorescence products at HORIBA, said, “The Veloci™ Biopharma Analyzer is a significant advancement of our core A-TEEM™ spectroscopy product line by offering our industrial partners easy workflows and multivariate analysis, a new open platform communications (OPC) unified architecture (UA) process analytical technology (PAT) interface and full compliance solutions.”

Andrew Whitley, Vice President and Field Officer for the HORIBA Life Science Business Field said, “The pharmaceutical industry is increasingly using fluorescence spectroscopy, and more specifically, ATEEM™ for QA/QC and as a process analytical technology (PAT) for manufacturing control. A-TEEM™ provides similar information to mass spectrometry and chromatography, but faster and easier, typically no consumables, while like any optical technique is easily implemented. Andrew continued, “Veloci’s ATEEM™ Technology offers the speed, cost-effectiveness and solutions required across research, PAT and QA/QC.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>